The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bristol-Myers Squibb; Ono Pharmaceutical
Research Funding - MSD (Inst)
Other Relationship - Bayer; Novartis; Pfizer
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
 
Brian I. Rini
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche/Genentech; synthorx
Research Funding - AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Horizon Pharma; Incyte; Inovio Pharmaceuticals; Janssen; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst); US Patent No: 15/226,474 files on 7/1/15 (Inst)
 
Viktor Stus
Research Funding - MSD (Inst)
 
Rustem Gafanov
Research Funding - MSD (Inst)
 
Robert Hawkins
Stock and Other Ownership Interests - Immetacyte
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer
Research Funding - MSD (Inst)
Patents, Royalties, Other Intellectual Property - MRC Phage
 
Dmitry Nosov
Research Funding - MSD (Inst)
 
Frederic Pouliot
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen; Pfizer; Roche; Sanofi
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Sanofi
Research Funding - Astellas Pharma (Inst); MSD (Inst); Sanofi (Inst)
Other Relationship - Astellas Pharma; Bayer; Sanofi
 
Denis Soulieres
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Ipsen; Merck; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Bohuslav Melichar
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - MSD (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Roche
 
Ihor Vynnychenko
No Relationships to Disclose
 
Sergio Jobim Azevedo
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Delphine Borchiellini
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Novartis; Pfizer
Research Funding - MSD (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Jens Bedke
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; MSD; Nektar; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Satoshi Tamada
No Relationships to Disclose
 
Shuyan Wan
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Rodolfo F. Perini
Employment - Merck
Patents, Royalties, Other Intellectual Property - Merck
 
Mei Chen
Employment - Merck
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Merck; Newlink Genetics/Pharmatech; Novartis; Oncolys BioPharma; Pfizer; Surface Oncology; Werewolf Pharma; X4 Pharma
Research Funding - Bristol-Myers Squibb (Inst)
 
Thomas Powles
Honoraria - AstraZeneca; Bristol-Myers Squibb; MERCK; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Incyte; Ipsen; Merck; Novartis; Novartis; Pfizer; Seagen
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis/Ipsen; Pfizer; Roche/Genentech